| T vs. C | trastuzumab | lapatinib plus epirubicin and cyclophosphamide followed by docetaxel | trastuzumab plus endocrine therapy | trastuzumab emtansine | trastuzumab plus epirubicin and cyclophosphamide followed by docetaxel | trastuzumab emtasine plus endocrine therapy |
| trastuzumab | --- | NA | NA | NA | NA | NA |
| lapatinib plus epirubicin and cyclophosphamide followed by docetaxel | NA | --- | NA | NA | NA | NA |
| trastuzumab plus endocrine therapy | NA | NA | --- | NA | NA | NA |
| trastuzumab emtansine | NA | NA | NA | --- | NA | NA |
| trastuzumab plus epirubicin and cyclophosphamide followed by docetaxel | NA | NA | NA | NA | --- | NA |
| trastuzumab emtasine plus endocrine therapy | NA | NA | NA | NA | NA | --- |
pathologies: 145 - treatments: 1433 result logic
-
About us
-
Contact us
-
Method
-
RSS
Made with
in Lyon
-
Credits
-
Privacy policy
-
